JCO Flashback: Cisplatin Plus Gemcitabine Vs. Cisplatin Plus Pemetrexed-A Comparative Analysis (2008)

被引：0
|
作者：
不详
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 14期
关键词：
D O I：
10.1200/JCO.23.00256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2457 / 2457
页数：1
相关论文
共 50 条
  • [21] Phase III study of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC; interim analysis
    Kosmas, C.
    Angel, J.
    Athanasiou, A.
    Rapti, A.
    Karanikas, C.
    Lambaki, S.
    Politis, N.
    Mylonakis, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 531 - 531
  • [22] Comparison of three induction chemotherapy regimens with gemcitabine plus cisplatin, cisplatin plus fluorouracil, and cisplatin plus capecitabine for locoregionally advanced nasopharyngeal carcinoma: A pooled analysis of two prospective studies
    Chan, S. K.
    Choi, C. W.
    Chan, S. Y.
    Tong, C. C.
    Lam, K. O.
    Kwong, D. L. W.
    Leung, T. W.
    Luk, M. Y.
    Lee, A. W. M.
    Lee, V. H. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S1348 - S1348
  • [23] Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
    Galsky, Matthew D.
    Pal, Sumanta K.
    Chowdhury, Simon
    Harshman, Lauren C.
    Crabb, Simon J.
    Wong, Yu-Ning
    Yu, Evan Y.
    Powles, Thomas
    Moshier, Erin L.
    Ladoire, Sylvain
    Hussain, Syed A.
    Agarwal, Neeraj
    Vaishampayan, Ulka N.
    Recine, Federica
    Berthold, Dominik
    Necchi, Andrea
    Theodore, Christine
    Milowsky, Matthew I.
    Bellmunt, Joaquim
    Rosenberg, Jonathan E.
    CANCER, 2015, 121 (15) : 2586 - 2593
  • [24] A cost effectiveness analysis of bevacizumab plus cisplatin and gemcitabine (BCG) compared with induction pemetrexed plus cisplatin (iPC) for the treatment of advanced or recurrent non-small cell cancer (NSCLC) in Germany
    Bischoff, Helge
    Heigner, David
    Wiesner, Christof
    Walzer, Stefan
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S666 - S667
  • [25] Pemetrexed plus cisplatin versus docetaxel plus cisplatin for stage IV lung adenocarcinoma based on propensity score matching
    Su, ShengFa
    Liu, LingFeng
    Geng, YiChao
    Ouyang, WeiWei
    Ma, Zhu
    Li, QingSong
    Zhao, ChaoFen
    Li, Mei
    Wang, Yu
    Luo, DaXian
    Yang, WenGang
    He, ZhiXu
    Lu, Bing
    ANTI-CANCER DRUGS, 2019, 30 (03) : 295 - 301
  • [26] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Manegold, C.
    Digumarti, R.
    Zukin, M.
    de Marinis, F.
    Mellerngaard, A.
    Gandara, D.
    Simms, L.
    Kaiser, C.
    Blatter, J.
    Gatzemeier, U.
    EJC SUPPLEMENTS, 2007, 5 (06): : 9 - 9
  • [27] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Scagliotti, Giorgio
    Purvish, Parikh
    von Pawel, Joachim
    Biesma, Bonna
    Vansteenkiste, Johan
    Manegold, Christian
    Simms, Lorinda
    Posther, Sugarman Katherine
    Obasaju, Coleman
    Blatter, Johannes
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S306 - S306
  • [28] Gemcitabine alone or plus cisplatin for biliary tract cancer?
    Scheithauer, Werner
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (10) : 554 - 555
  • [29] Gemcitabine alone or plus cisplatin for biliary tract cancer?
    Werner Scheithauer
    Nature Reviews Clinical Oncology, 2010, 7 : 554 - 555
  • [30] An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)
    Walzer, S.
    de Castro Carpeno, J.
    Vergnenegre, A. V.
    Chouaid, C.
    Heigener, D. F. H.
    Bischoff, H. G.
    Nicolson, M. C.
    Aultman, R.
    Siebert, U.
    EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 555
12345